FindMyKOL
Clinical trialNCT06797024RecruitingInterventional

JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

NCT06797024 is an interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies JY231 Injection in Autoimmune Diseases of the Nervous System. The registry lists an enrollment of 20 participants at 1 site in 1 country. The registry lists a start date of 28 Feb 2025 and a primary completion date of 31 Dec 2026. One of its registered investigators has a FindMyKOL profile.

SponsorTongji Hospital →Enrollment20Autoimmune Diseases of the Nervous System
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06797024
FieldValue
Registry IDNCT06797024
StatusRecruiting
Study typeInterventional trial
Lead sponsorTongji Hospital
Enrollment20
Registered sites1
Countries1
ConditionsAutoimmune Diseases of the Nervous System
DrugsJY231 Injection
Start28 Feb 2025
Primary completion31 Dec 2026
Study completion31 Mar 2027
Last update posted31 May 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

his study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory neurologic immune disorders. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed/refractory neurologic immune disorders.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei

    Bitao Bu, MDChuan Qin, MDChunrui Li, MDDaishi Tian, MDDi Wang, MDJianfeng Zhou, MDMin Zhang, MDWei Wang, MD
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

JY231 Injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06797024

Each answer restates registry values shown on this page.

What is NCT06797024?

NCT06797024 is an interventional trial sponsored by Tongji Hospital. It studies JY231 Injection in Autoimmune Diseases of the Nervous System.

Is NCT06797024 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06797024?

The registry names Chuan Qin (principal investigator, Tongji Hospital), Dai-shi Tian, PhD (principal investigator, Tongji Hospital) and Wei Wang, PhD (principal investigator, Tongji Hospital) as overall officials.

Where does NCT06797024 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT06797024 study?

The registered drug and biological interventions are JY231 Injection.

When is NCT06797024 expected to complete?

The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Mar 2027. The sponsor last updated the record on 31 May 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.